Pfizer Patent Not Indefinite In Sandoz IP Row, Judge Says
A Delaware federal judge ruled Wednesday that a Pfizer Inc. patent related to the overactive-bladder medication Toviaz, which the company asserted against Sandoz Inc. and others, is not invalid as indefinite....To view the full article, register now.
Already a subscriber? Click here to view full article